HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study)

Abstract

Patrick Mercié: data collection and draft reviewing and editing. Fabienne Marcellin: study conception and draft reviewing and editing. Laure Esterle: data collection and draft reviewing and editing. Claudine Duvivier: data collection and draft reviewing and editing. Elina Teicher: data collection and draft reviewing and editing. Morgane Bureau: draft reviewing and editing. Julie Chas: data collection and draft reviewing and editing. Dominique Salmon-Céron: data collection and draft reviewing and editing. Philippe Sogni: data collection and draft reviewing and editing. Maria Patrizia Carrieri: study conception and draft reviewing and editing. Linda Wittkop: data collection, methodological support and draft reviewing and editing.Camelia Protopopescu: study conception, statistical analyses and draft reviewing and editing.

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

“…Moreover, both drugs seem to reinforce each other [ 34 , 35 ]. Accordingly, cannabis use impairs the chances of tobacco cessation [ 36 ], including in HIV–HCV co-infected people [ 15 ]. This phenomenon has also been documented for polysubstance use generally speaking [ 37 , 38 ].…”

“…This clinical change impacts quality of life [ 6 – 10 ] and foster behavioral changes [ 10 , 11 ]. As psychoactive substance use is highly prevalent in HIV–HCV co-infected patients [ 12 – 15 ], we may expect HCV cure to impact substance use behavior. The benefits of cannabis and cannabinoid use for HIV infection management and less severe treatment side-effects, are widely recognized [ 16 , 17 ], and PLWH frequently report their therapeutic use [ 18 – 22 ].…”

“…However, cannabis use may also promote pulmonary disease [ 23 ] and cognitive impairments in PLWH [ 24 ]. As cannabis use [ 14 , 15 , 21 ] and cannabis dependence [ 25 ] are frequent in HIV–HCV co-infected patients, it is important to explore changes in use after HCV cure. Using data from a cross-sectional survey embedded in the ANRS CO13 HEPAVIH cohort, we aimed to identify correlates of cannabis use reduction following HCV cure in HIV–HCV co-infected cannabis users, and to characterize persons who reduced their use.…”

Estimates of prevalence, time-trend, and association of smoking in adults living with HIV, HBV, and HCV (NHANES 1999–2018)

“…S1 ). Although advanced medical methods could ensure the quality of life of infected people, such as antiretroviral therapy (ART) and gene therapy for human immunodeficiency virus (HIV) 1 , 2 , antiviral therapies for hepatitis B virus (HBV) 3 and hepatitis C virus (HCV) 4 , 5 , the high smoking rate among infected people often led to poor efficacy 6 – 8 . For instance, tobacco smoking cessations among HIV and HCV infected people could increase the treatment efficiency by 76% 6 .…”

“…Although advanced medical methods could ensure the quality of life of infected people, such as antiretroviral therapy (ART) and gene therapy for human immunodeficiency virus (HIV) 1 , 2 , antiviral therapies for hepatitis B virus (HBV) 3 and hepatitis C virus (HCV) 4 , 5 , the high smoking rate among infected people often led to poor efficacy 6 – 8 . For instance, tobacco smoking cessations among HIV and HCV infected people could increase the treatment efficiency by 76% 6 . In addition, compared to smokers without HIV, those with HIV had twice the risk of developing tuberculosis, a 6–15 year shorter lifespan 9 , and quitting smoking among people living with HIV decreased non-AIDS malignant-tumor by 34%, the risk of cardiovascular disease by 20%, as well as total mortality by 16% 10 .…”